Syros Pharmaceuticals (SYRS) Competitors $0.25 0.00 (-1.20%) (As of 12/4/2024 06:12 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SYRS vs. CERO, EQ, IBIO, CVKD, CMMB, ATHA, INAB, LPCN, GOVX, and LSTAShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include CERo Therapeutics (CERO), Equillium (EQ), iBio (IBIO), Cadrenal Therapeutics (CVKD), Chemomab Therapeutics (CMMB), Athira Pharma (ATHA), IN8bio (INAB), Lipocine (LPCN), GeoVax Labs (GOVX), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. CERo Therapeutics Equillium iBio Cadrenal Therapeutics Chemomab Therapeutics Athira Pharma IN8bio Lipocine GeoVax Labs Lisata Therapeutics Syros Pharmaceuticals (NASDAQ:SYRS) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings. Which has stronger earnings & valuation, SYRS or CERO? CERo Therapeutics has lower revenue, but higher earnings than Syros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyros Pharmaceuticals$386K17.15-$164.57M-$3.03-0.08CERo TherapeuticsN/AN/A-$2.54MN/AN/A Is SYRS or CERO more profitable? CERo Therapeutics' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syros PharmaceuticalsN/A -3,369.56% -97.04% CERo Therapeutics N/A N/A -108.43% Do institutionals and insiders believe in SYRS or CERO? 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Comparatively, 18.0% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, SYRS or CERO? Syros Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Does the media prefer SYRS or CERO? In the previous week, Syros Pharmaceuticals had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 3 mentions for Syros Pharmaceuticals and 1 mentions for CERo Therapeutics. CERo Therapeutics' average media sentiment score of 0.49 beat Syros Pharmaceuticals' score of 0.04 indicating that CERo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syros Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CERo Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor SYRS or CERO? Syros Pharmaceuticals received 367 more outperform votes than CERo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSyros PharmaceuticalsOutperform Votes36763.28% Underperform Votes21336.72% CERo TherapeuticsN/AN/A Do analysts rate SYRS or CERO? Syros Pharmaceuticals presently has a consensus price target of $3.33, suggesting a potential upside of 1,251.17%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Syros Pharmaceuticals is more favorable than CERo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummarySyros Pharmaceuticals beats CERo Therapeutics on 9 of the 13 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.62M$6.68B$5.26B$9.14BDividend YieldN/A7.94%5.32%4.00%P/E Ratio-0.0811.24122.2518.12Price / Sales17.15337.941,285.8183.12Price / CashN/A59.1742.7838.57Price / Book0.315.444.834.96Net Income-$164.57M$152.49M$119.52M$224.92M7 Day Performance-7.78%8.32%3.27%2.22%1 Month Performance-90.25%4.89%2.64%9.35%1 Year Performance-91.25%29.02%32.70%28.46% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals4.3913 of 5 stars$0.25-1.2%$3.33+1,251.2%-91.4%$6.70M$9.94M-0.08120Gap UpCEROCERo TherapeuticsN/A$0.17-9.6%N/AN/A$26.23MN/A0.008Gap DownEQEquillium2.5271 of 5 stars$0.73-2.4%$5.00+581.8%+38.3%$25.98M$45.91M-5.3640Gap UpIBIOiBio0.9019 of 5 stars$2.83-3.7%$4.30+51.9%N/A$25.89M$175,000.000.00100Gap UpCVKDCadrenal Therapeutics2.5102 of 5 stars$15.50+2.0%$18.00+16.1%N/A$25.73MN/A-2.274Gap UpCMMBChemomab Therapeutics3.5398 of 5 stars$1.79-1.6%$7.33+309.7%+221.2%$25.70MN/A-1.8820Positive NewsGap UpATHAAthira Pharma2.5236 of 5 stars$0.65-1.3%$13.83+2,038.4%-63.0%$25.02MN/A-0.2340INABIN8bio3.4301 of 5 stars$0.35+13.2%$7.75+2,146.4%-66.5%$25.01MN/A-0.5120High Trading VolumeLPCNLipocine2.9702 of 5 stars$4.50-0.9%$10.00+122.2%+79.9%$24.08M$500,000.00-5.5110GOVXGeoVax Labs2.719 of 5 stars$2.55-3.4%$14.20+456.9%-62.9%$24.06M$3.09M0.0017LSTALisata Therapeutics3.2899 of 5 stars$2.80+1.4%$15.00+435.7%+21.2%$23.51MN/A-1.1230Positive News Related Companies and Tools Related Companies CERO Alternatives EQ Alternatives IBIO Alternatives CVKD Alternatives CMMB Alternatives ATHA Alternatives INAB Alternatives LPCN Alternatives GOVX Alternatives LSTA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYRS) was last updated on 12/5/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRS Stock Alerts